EN | DE

Dr. Andreas Kany

Über

Andreas Kany promovierte bei HIPS-DDOP über die Entwicklung von Inhibitoren bakterieller Collagenasen. Aktuell ist er als Postdoc verantwortlich für in vitro ADME, Bioassay- und Formulierungsentwicklung


2023

Inhibitors of the Elastase LasB for the Treatment of Pseudomonas aeruginosa Lung Infections

Konstantinovic J, Kany A, Alhayek A, Abdelsamie A, Sikandar A, Voos K, Yao Y, Andreas A, Shafiei R, Loretz B, …, Haupenthal J, Hirsch A (2023)

ACS Cent. Sci. 9 (12): 2205-2215DOI: 10.1021/acscentsci.3c01102

New Genetically Engineered Derivatives of Antibacterial Darobactins Underpin Their Potential for Antibiotic Development

Seyfert C, Müller A, Walsh D, Birkelbach J, Kany A, Porten C, Yuan B, Krug D, Herrmann J, Marlovits T, Hirsch A, Müller R (2023)

J. Med. Chem.DOI: 10.1021/acs.jmedchem.3c01660

Clean Synthetic Strategies to Biologically Active Molecules from Lignin: A Green Path to Drug Discovery

Afanasenko A, Wu X, Santi A, Elgaher W, Kany A, Shafiei R, Schulze M, Schulz T, Haupenthal J, Hirsch A, Barta K (2023)

Angew. Chem. Int. Ed.DOI: 10.1002/anie.202308131

Disrupting Kaposi's Sarcoma-Associated Herpesvirus (KSHV) Latent Replication with a Small Molecule Inhibitor

Berwanger A, Stein S, Kany A, Gartner M, Loretz B, Lehr C, Hirsch A, Schulz T, Empting M (2023)

Journal of medicinal chemistry 66 (15): 10782-10790DOI: 10.1021/acs.jmedchem.3c00990

New Genetically Engineered Derivatives of Antibacterial Darobac-tins Underpin their Potential for Antibiotic Development

Seyfert C, Müller A, Walsh D, Birkelbach J, Kany A, Porten C, Yuan B, Krug D, Herrmann J, Marlovits T, Hirsch A, Müller R (2023)

BookDOI: 10.26434/chemrxiv-2023-24tmj

Inhibitors of the Elastase LasB for the treatment of Pseudomonas aeruginosa lung infections

Konstantinovic J, Kany A, Alhayek A, Abdelsamie A, Sikandar A, Voos K, Yao Y, Andreas A, Shafiei R, Loretz B, …, Haupenthal J, Hirsch A (2023)

DOI: 10.26434/chemrxiv-2023-bszcb

Impact of Drug Administration Routes on the In Vivo Efficacy of the Natural Product Sorangicin a Using a Staphylococcus aureus Infection Model in Zebrafish Embryos

Fries F, Kany A, Rasheed S, Hirsch A, Müller R, Herrmann J (2023)

International journal of molecular sciences 24 (16)DOI: 10.3390/ijms241612791

Selective Activation of TRPC6 Ion Channel by Metallated Type-B Polyprenylated Polycyclic Acylphloroglucinols

Peslalz P, Kraus F, Izzo F, Bleisch A, El Hamdaoui Y, Schulz I, Kany A, Hirsch A, Friedland K, Plietker B (2023)

ManuscriptDOI: 10.26434/chemrxiv-2023-6w94r

The natural product chlorotonil A preserves colonization resistance and prevents relapsing Clostridioides difficile infection

Bublitz A, Brauer M, Wagner S, Hofer W, Müsken M, Deschner F, Lesker T, Neumann-Schaal M, Paul L, Nübel U, …, Fuchs T, Strowig T (2023)

Cell Host MicrobeDOI: 10.1016/j.chom.2023.04.003

Towards Translation of PqsR Inverse Agonists: From In Vitro Efficacy Optimization to In Vivo Proof-of-Principle

Hamed M, Abdelsamie A, Rox K, Schütz C, Kany A, Röhrig T, Schmelz S, Blankenfeldt W, Arce-Rodriguez A, Borrero-de Acuña J, …, Hartmann R, Empting M (2023)

Adv. Sci. (Online)DOI: 10.1002/advs.202204443

2022

Screening of Natural Products and Small Molecules Uncovers Novel Coronavirus 1a/1b Frameshifting Inhibitors with Antiviral Properties

Kibe A, Elgaher W, Rand U, Zimmer M, Kany A, Hermann J, Müller R, Cicin-Sain L, Hirsch A, Caliskan N (2022)

SSRN JournalDOI: 10.2139/ssrn.4157446

N-Aryl Mercaptopropionamides as Broad-Spectrum Inhibitors of Metallo-β-Lactamases

Kaya C, Konstantinovic J, Kany A, Andreas A, Kramer J, Brunst S, Weizel L, Rotter M, Frank D, Yahiaoui S, …, Wichelhaus T, Hirsch A (2022)

Journal of medicinal chemistry 65 (5): 3913-3922DOI: 10.1021/acs.jmedchem.1c01755

Inhibitors of Pseudomonas aeruginosa virulence factor LasB

Ducho C, Hartmann R, Haupenthal J, Hirsch A, Kany A, Kaya C, Konstantinovic J, Voos K, Walter I, Yahiaoui S, …, Jumde R, Kiefer A (2022)

Patent A61K31/095; A61K31/10; A61K31/167; A61K31/4184; A61K31/426; A61K31/428; A61K31/4406; A61P31/04; C07C323/60; C07D213/74; C07D235/30; C07D277/46; C07D277/82; C07D333/36; C07F9/38; C07F9/40; (WO2022043322A1)

2021

N-Phenyl-3-Mercaptopropanamide Derivatives as Metallo-Beta-Lactamase Inhibitors for the Treatment of Bacterial Infections

Hartmann R, Konstantinovic J, Haupenthal J, Hirsch A, Kany A, Kaya C, Yahiaoui S, Wichelhaus T, Proschak E (2021)

Patent A61K31/5375; A61P31/04; C07C233/15; C07C233/25; C07C233/33; C07C233/43; C07C233/54; C07C319/02; C07C323/52; C07D295/22; (‌‌WO2021191219A1)

N-Phenyl-3-Mercaptopropanamide Derivatives as Metallo-Beta-Lactamase Inhibitors for the Treatment of Bacterial Infections

Hartmann R, Konstantinovic J, Haupenthal J, Hirsch A, Kany A, Kaya C, Yahiaoui S, Wichelhaus T, Proschak E (2021)

Patent A61K31/5375; A61P31/04; C07C233/15; C07C233/25; C07C233/33; C07C233/43; C07C233/54; C07C319/02; C07C323/52; C07D295/22; (‌‌WO2021191219A1)

New PqsR Inverse Agonist

Schütz C, Empting M, Ahmed S, Hamed M, Hartmann R, Röhrig T, Kany A, Hirsch A (2021)

Patent A61K31/4439; A61K31/506; A61P31/04; C07D401/12; C07D403/12; (WO2021136803A1)

New PqsR Inverse Agonist

Schütz C, Empting M, Ahmed S, Hamed M, Hartmann R, Röhrig T, Kany A, Hirsch A (2021)

Patent A61K31/4439; A61K31/506; A61P31/04; C07D401/12; C07D403/12; (WO2021136803A1)

Novel PqsR Inverse Agonists

Hamed M, Ahmed S, Empting. M., Schütz C, Hartmann R, Röhrig T, Kany A, Hirsch A (2021)

Patent A61K31/4439; A61P31/04; C07D401/14; C07D417/14; (WO2021136805A1)

Novel PqsR Inverse Agonists

Hamed M, Ahmed S, Empting. M., Schütz C, Hartmann R, Röhrig T, Kany A, Hirsch A (2021)

Patent A61K31/4439; A61P31/04; C07D401/14; C07D417/14; (WO2021136805A1)

Substrate-Inspired Fragment Merging and Growing Affords Efficacious LasB Inhibitors

Kaya C, Walter I, Yahiaoui S, Sikandar A, Alhayek A, Konstantinovic J, Kany A, Haupenthal J, Köhnke J, Hartmann R, Hirsch A (2021)

Angewandte Chemie (International ed. in English)DOI: 10.1002/anie.202112295

A New PqsR Inverse Agonist Potentiates Tobramycin Efficacy to Eradicate Pseudomonas aeruginosa Biofilms

Schütz C, Ho D, Hamed M, Abdelsamie A, Röhrig T, Herr C, Kany A, Rox K, Schmelz S, Siebenbürger L, …, Lehr C, Empting M (2021)

Advanced science (Weinheim, Baden-Wurttemberg, Germany) 8 (12)DOI: 10.1002/advs.202004369

2020

Micro-rheological properties of lung homogenates correlate with infection severity in a mouse model of Pseudomonas aeruginosa lung infection

Murgia X, Kany A, Herr C, Ho D, Rossi C, Bals R, Lehr C, Hirsch A, Hartmann R, Empting M, Röhrig T (2020)

Scientific Reports 10 (1)DOI: 10.1038/s41598-020-73459-5

N -Aryl-3-mercaptosuccinimides as Antivirulence Agents Targeting Pseudomonas aeruginosa Elastase and Clostridium Collagenases

Konstantinovic J, Yahiaoui S, Alhayek A, Haupenthal J, Schönauer E, Andreas A, Kany A, Müller R, Koehnke J, Berger F, …, Brandstetter H, Hirsch A (2020)

J. Med. Chem. 63 (15): 8359-8368DOI: 10.1021/acs.jmedchem.0c00584

Novel PqsR Inverse Agonists

Hamed M, Ahmed S, Empting. M., Schütz C, Hartmann R, Röhrig T, Kany A, Hirsch A (2020)

Patent (EP20150119)

2018

Tackling Pseudomonas aeruginosa Virulence by a Hydroxamic Acid-Based LasB Inhibitor

Kany A, Sikandar A, Yahiaoui S, Haupenthal J, Walter I, Empting M, Köhnke J, Hartmann R (2018)

ACS chemical biology 13 (9): 2449-2455DOI: 10.1021/acschembio.8b00257